MG
GLUE icon

Michael Gelband’s Monte Rosa Therapeutics GLUE Stock Holding History

Michael Gelband’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100,000
Closed -$630K – 1659
2023
Q4 		$630K Buy
+100,000
New +$392K ﹤0.01% 972

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's GLUE Position: Q2 2026 in Review

Michael Gelband opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 121,121 shares worth $2.93M. The stake represents 0.02% of the portfolio and ranks #669 among its holdings. This is a return to the name: Michael Gelband previously reported a position in GLUE as recently as Q2 2025.

Michael Gelband first reported a position in GLUE in Q1 2023 and has held it in 10 quarters since. The position peaked at $4.59M in Q2 2023. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Michael Gelband held 121,121 shares of Monte Rosa Therapeutics worth $2.93M as of Q2 2026.
  • Monte Rosa Therapeutics was a new Michael Gelband position in Q2 2026.
  • Monte Rosa Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #669 holding.
  • Michael Gelband first reported a position in Monte Rosa Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Michael Gelband's Monte Rosa Therapeutics position peaked at $4.59M in Q2 2023.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.